Search Results 131-140 of 16765 for GLP-1 agonists

  1. Publications - Meera Shah, M.B., Ch.B. - Mayo Clinic

    Contribution of endogenous glucagon-like peptide-1 to changes in glucose ... Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014 Sep ...

  2. A New Protocol and Normative Values for the Evaluation of Gastric Emptying and Gastric Accommodation to Treat Bariatric Surgery Patients - Mayo Clinic

    Use of drugs known to alter gastrointestinal function including opiates, GLP1 agonists and analogs and medications known to affect gastric emptying. History ...

  3. Glucagon (injection route) - Side effects & dosage - Mayo Clinic

    If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Aclidinium; Amantadine ...

  4. Dr. Rozalina McCoy Archives - Mayo Clinic News Network

    ... GLP-1 receptor agonist (GLP-1RA) and SGLT2 inhibitor (SGLT2i) medications. For example, GLP-1RA medications reduce the risk of cardiovascular events, kidney ...

  5. Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Mayo Clinic

    ... 1 trial. Phase 4 trials look at long-term safety and effectiveness ... Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP ...

  6. Glimepiride (oral route) - Side effects & dosage - Mayo Clinic

    For type 2 diabetes: Adults—At first, 1 to 2 milligrams (mg) once a day. Your doctor may adjust your dose until your blood sugar is controlled ...

  7. GERD: Can certain medications make it worse? - Mayo Clinic

    Medicines and dietary supplements that can irritate the esophagus and cause heartburn pain that is like the pain of GERD include: Antibiotics, such as ...

  8. Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus - Mayo Clinic

    ... 1 trial. Phase 4 trials look at long-term safety and effectiveness, after ... Current treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) ...

  9. Type 1 Diabetes Clinical Trials - Mayo Clinic Research

    The purpose of this study is to demonstrate that a morning injection of Toujeo compared to Lantus will provide better glycemic control, as shown by Continuous ...

  10. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease - Mayo Clinic

    ... 1 trial. Phase 4 trials look at long-term safety and ... Use of any glucagon-like peptide-1 (GLP-1) receptor agonist within 30 days prior to screening.